Healthcare
Turn Therapeutics Inc.(TTRX)
Live Price
Offline$6.05
+3.16% today
Window Change
-13.64%
Window
Oct 8, 2025 โ Jun 12, 2026
- Market Cap
- $110.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -76.9%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 171 bars ยท Oct 8, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Turn Therapeutics Inc. (TTRX) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $6.04 and down 13.6% across the available one-year price window (Oct 8, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -76.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -76.9%, free cash flow -85.9% with operating margin 0.0% and ROIC -94.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TTRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -76.9%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.2% | +18.7% | +46.1% |
2026 Mar 31, 2026 | -76.5% | -2.7% | +9.4% | +11.1% |
2025 Nov 13, 2025 | โ | -2.2% | -33.7% | -16.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TTRX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TTRX Max Drawdown
-70.54%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TTRX and SPY.
Company Overview
Turn Therapeutics Inc.
NASDAQ Global Select
Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.
- Leadership
- Bradley E. Burnam
- IPO Date
- Oct 8, 2025
- Employees
- 2
- Street Address
- 250 N Westlake Blvd
- Mailing
- Westlake Village, CA, 91362
- Region
- Westlake Village, CA, US
- Reporting Currency
- USD
- Investor Line
- 818 546 4011
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 11.1
Growth
- Revenue
- 0.0%
- EPS
- -76.9%
- Free Cash Flow
- -85.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -141.7%
- ROIC
- -94.4%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 0.87
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.